期刊文献+

体外诱导人型支原体对氟喹诺酮类药物耐药的实验研究 被引量:1

Study on drug resistance of mycoplasma hominis induced by fluoroquinolones in vitro
下载PDF
导出
摘要 目的探讨体外短期和长期诱导后人型支原体(Mh)对氟喹诺酮类药物的耐药和交叉耐药情况。方法将Mh标准株PG21在分别含有次抑菌浓度环丙沙星、氧氟沙星、司帕沙星和加替沙星的液体培养基中传代培养3代和12代后,筛选诱导株并分别检测其对4种药物的MIC值。结果经体外诱导后,分别筛选出4株短期诱导株(传3代)和4株长期诱导株(传12代)。4株短期诱导株对诱导药物和非诱导药物均产生耐药和交叉耐药,但耐药程度较低;4株长期诱导株的耐药和交叉耐药程度大大提高;且这种体外获得性耐药具有较好的稳定性。结论体外长时间、次抑菌浓度的氟喹诺酮类药物刺激将诱导Mh产生稳定的耐药和交叉耐药;短期诱导产生低度耐药,长期诱导产生高度耐药。 Objective To explore the drug resistance or cross-resistance of mycoplasma hominis after 3-passage and 12-passage induction by fluoroquinolones in vitro. Methods The mycoplasma hominis standard strain PG21 were cultured stepwise for 3 and 12 passages respectively with ciprofloxacin,ofloxacin, sparfloxacin and gatifloxacin at subinhibitory concentrations and the minimum inhibition concentrations(MICs) to these drugs were detected before and after induction. Results Four 3-passage and four 12-passage resistant strains were selected respectively after induced by fluoroquinolones in vitro. Four 3-passage selected strains exhibited low-lever resistance or cross-resistance and another four 12-passage selected strains exhibited high lever resistance or cross resistance to these fluoroquinolones. The resistance or cross-resistance of mycoplasma hominis induced by fluoroquinolones in vitro were stable. Conclusion The resistance and cross-resistance of mycopiasma hominis to fluoroquinolones can be induced after long time and subinhibitory concentration stimulation with the fluoroquinolones in vitro. Low-lever and high lever resistance or cross-resistance were selected after 3-passage and 12 passage induction respectively.
出处 《重庆医学》 CAS CSCD 北大核心 2009年第6期659-660,共2页 Chongqing medicine
基金 深圳市科技计划基金资助项目(200603087)
关键词 人型支原体 氟喹诺酮 耐药性 mycoplasma hominis(Mh) fluoroquinolone drug resistance
  • 相关文献

参考文献4

  • 1Wu YM,Zeng YH,Yao YB,et al. Susceptibilities of mycololasma hominis and ureaplasma urealyticum to fluoroquinolones[J]. Clin J Sex Transm Infect,2004,4(1):28.
  • 2Bebear CM, Renaudin H, Charron A, et al. Alterations in topoisomerase Ⅳ and DNA gyrase in quinotone-resistant mutants of mycoplasma hominis obtained in vitro[J]. Antimicrob Agents Chemother, 1998,42(9) : 2304.
  • 3Gruson D, Pereyre S, Renaudin H, et al. In vitro development of resistance to six and four fluoroquinolones in mycoplasma pneumoniae and mycoplasma hominis, respectively[J]. Antimicrob Agents Chemother, 2005,49 (3) : 1190.
  • 4叶萍,王晓川,吴志华.人型支原体氟喹诺酮耐药性的分子机制[J].中国麻风皮肤病杂志,2005,21(10):805-807. 被引量:10

二级参考文献14

  • 1Bebear CM, Bove JM, Bebear C, et al. Characterization of mycoplasma hominis mutations involved in resistance to fluoroquinolones.Antimicrob Agents Chemother 1997 ;41 : 269 - 273.
  • 2Bebear CM, Renaudin H, Charron A, et al. Alterations in topoisomerase IV and DNA gyrase in quinolone - resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother 1998;42:2304 - 2311.
  • 3Bebear CM, Renaudin J, Charron A, et al. Mutations in the gyrA,parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob Agents Chemother 1999;43:954 - 956.
  • 4Bebear CM, Renaudin H, Charron A, et al. DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones. Antimicrob Agents Chemother 2003 ;47 : 3323 - 3325.
  • 5Govonm VM, Gushchin AE, Ladygina VG, et al. Formation of M.hominis and A. laidlawii resistance to fluoroquinolones. Mol Gen Mikrobiol Virusol 1998;3:16 - 19.
  • 6Gushchin AE, Taganov KD, Topoi' IuIu, et al. Use of a method of single- stranded DNA fragment conformation polymorphism (SSCP)for detecting resistance of mycoplasm hominis to fluoroquinolones.Mol Gen Mikrobiol Virusol 1998;4:37- 40.
  • 7Gruson D, Pereyre S, Renaudin H, et al. In vitro development of resistance to six and four fluoroquinolones in mycoplasma pneumoniae and mycoplasma hominis, respectively. Antimicrobial Agents and Chemotherapy 2005 ; 49: 1190 - 1193.
  • 8Bebear CM, Charron A, Bove JIM, et al. Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis. Antimicrob Agents Chemother 1998,42:2024- 2031.
  • 9Kenny GE, Young PA, Cartwright FD, et al. Sparfloxacin selects gyrase mutations in first - step mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations. Antimicrob Agents Chemother 1999 ;43 : 2493 - 2496.
  • 10Gushchin AE, Ladygina VG, Govorun VM. Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones. Mol Gen Mikrobiol Virusol 1999;4:19- 24.

共引文献9

同被引文献9

  • 1吴仪谋,叶元康.支原体学[M].人民卫生出版社,2008:16-25.
  • 2Sato T, Okubo T, Usui M, et al. Amino acid substitutions in Gy- rA and ParC are associated with fluoroquinolone resistance in My- coplasma bovis isolates from Japanese dairy calves[ J]. Journal of Veterinary Medical Science, 2013, 75 (B) : 1063 - 1065.
  • 3Clinical and Laboratory Standards Insitute. Performance standards for antirnicrobial susceptibility testing: approved standard [ M ]. CLSI document, 2012 : MIO0 - $22.
  • 4Soehnlen M K, Kunze M E, Karunathilake K E, et al. In vitro antimicrobial inhibition of Mycoplasma bovis isolates submitted to the pennsylvania animal diagnostic laboratory using flow cytometry and a broth microdilution method[ J]. Journal of Veterinary Diag- nostic Irlvestigation, 2011, 23 (3) : 547 - 55 I.
  • 5Lysnyansky I, Mikula I, Gerchman I, et al. Rapid detection of a point mutation in the parC gene associated with decreased suscep- tibi|ity to fluoroquinolones in Mycoplasma bovis [ J ]. Antimicrob Agents Chemother, 2009, 53(11) : 4911 -4914.
  • 6刘轶秋,吴聪明,沈建忠,李蓓蓓,张瑞婷,赵晖.3种禽源支原体替米考星耐药株的体外诱导及23S rRNA基因V域碱基突变分析[J].畜牧兽医学报,2011,42(7):981-987. 被引量:5
  • 7张利,李玉平,黎晓敏,尼玛仓木拉.牛支原体药物敏感性试验[J].动物医学进展,2012,33(2):110-113. 被引量:15
  • 8孔令聪,张春艳,高云航,马红霞.牛支原体耐药性研究进展[J].中国兽药杂志,2013,47(9):63-66. 被引量:7
  • 9高铎,孔令聪,王梓,马红霞.牛支原体的分离鉴定及其体外药物敏感性分析[J].中国兽药杂志,2014,48(3):66-68. 被引量:9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部